Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer
Glossary on
Printer Friendly Page Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer

Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer identifier:


Study Contact Information:

For additional information, please contact: 1-888-577-8839 or [email protected]

Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer

About the Study

The purpose of this study is to compare the effectiveness of using a combination of the drug pembrolizumab (Keytruda) and the lenvatinib (Lenvima) in women with III, IV, or recurrent endometrial cancer versus using chemotherapy treatment alone. NOTE: This study has completed enrollment.

Type of Study

This is a 2-arm, , phase 3 study.  

  • The study has two arms, which means patients will be placed into one of two groups. 
    • Patients assigned to Group 1 will receive will receive lenvatinib and pembrolizumab
    • Patients assigned to Group 2 will receive the chemotherapy drugs paclitaxeland carboplatin
  • The study is . Patients will be selected by chance and placed into one of the two groups.
  • The study is , all patients will know which group they have been placed into. 

What the Study Entails

  • Group 1 participants will take lenvatinib daily (orally) and will receive pembrolizumab intravenously once at the start of each 3-week treatment cycle.
  • Group 2 participants will receive chemotherapy medications paclitaxel intravenously and carboplatin intravenously on Day 1 of each 3-week treatment cycle.  

Follow up

  • Progression-free survival (the length of time that a patient survives without progression of the disease) of patients in this study will be measured for up to approximately 31 months.
  • Overall survival of patients will be followed for up to approximately 45 months.

Study Sites

Alabama Arizona California Colorado Connecticut
Georgia Louisiana Maine Minnesota New Jersey
New York North Carolina North Dakota Oregon South Dakota
Texas Washington      



  • Mobile: University of South Alabama, Mitchell Cancer Institute
    Contact: 251-445-9834     


  • Tucson: Arizona Oncology Associates PC- HOPE
    Contact: 281-863-6507   


  • Los Angeles: UCLA Hematology and Oncology Clinic (Westwood) 
    Contact: 310-794-6982     


  • Aurora: University of Colorado Cancer Center   
    Contact: 303-724-2066     


  • New Haven: Smilow Cancer Hospital at Yale New Haven       
    Contact: 203-785-6398     


  • Augusta: Georgia Cancer Center at Augusta University
    Contact: 706-721-4805     


  • Covington: Women's Cancer Care 
    Contact: 985-892-2252     


  • Scarborough: Maine Medical Partners
    Contact: 207-396-8376     


  • Minneapolis: Minnesota Oncology Hematology, PA 
    Contact: 281-863-6507     

New Jersey

  • Basking Ridge: Memorial Sloan-Kettering Cancer Center At Basking Ridge 
    Contact: 646-888-4224
  • Hackensack: John Theurer Cancer Center at Hackensack University Med Ctr         
    Contact: 551-996-4716
  • Middletown: Memorial Sloan Kettering Cancer Center- Monmouth
    Contact: 646-888-4466
  • Montvale: MSKCC-Bergen   
    Contact: 646-888-4466
  • Teaneck: Holy Name Medical Center      
    Contact: 201-227-6200     

New York

  • Commack: Memorial Sloan-Kettering Cancer Center at Commack
    Contact: 646-888-4466     
  • Harrison: Memorial Sloan Kettering Cancer Center - West Harrison        
    Contact: 646-888-4424
  • New York City:The Blavatnik Family- Chelsea Medical Center at Mount Sinai 
    Contact: 212-604-6059
  • New York City: Memorial Sloan Kettering Cancer Center      
    Contact: 646-888-4224 
  • Rochester: University of Rochester  
    Contact: 585-275-5345
  • Uniondale: Memorial Sloan Kettering Cancer Center - Nassau
    Contact: 646-888-4466     

North Carolina

  • Chapel Hill: University of North Carolina- Chapel Hill
    Contact: 919-966-4432  

North Dakota

  • Fargo: Roger Maris Cancer Center      
    Contact: 605-312-3250     


  • Eugene: Willamette Valley Cancer Institute and Research Center         
    Contact: 281-863-6507     

South Dakota

  • Sioux Falls: Sanford Cancer Center Oncology Clinic
    Contact: 605-312-3343     


  • Dallas: Parkland Health & Hospital System 
    Contact: 214-648-7097
  • Dallas: University of Texas Southwestern Medical Center
    Contact: 214-648-3026
  • The Woodlands: Texas Oncology-The Woodlands
    Contact: 281-863-6507     


  • Vancouver: Legacy Salmon Creek Medical Center    
    Contact: 503-413-8654     
This Study is Open To:

NOTE: This study has completed enrollment.

This Study is Not Open To: